Warscheid Lab - Targeted FLNc S2233 S2236 phosphorylation assay

Warscheid Lab - Targeted FLNc S2233 S2236 phosphorylation assay
Targeted FLNc S2233 S2236 phosphorylation assay

  • Organism: Homo sapiens, Mus musculus
  • Instrument: Q Exactive Plus
  • SpikeIn: Yes
  • Keywords: FLNc, phosphoproteomics, PRM assay
Abstract
In FLNc 10 phosphosites in FLNc (including S2234, S2237 and T2239) were found to be differentially phosphorylated. FLNc-pS2234 was by far the most abundant phosphosite followed by pS2237, while levels of FLNc-pT2239 were very low. pS2234 and pS2237 are part of the extended basophilic motif which is located in Ig-like domain 20 (d20)of FLNc. While levels of pS2234 and pS2234/pS2237 were strongly reduced following inhibition of PI3K/Akt signaling and increased upon IGF1-mediated stimulation, the levels were reversed for pS2237. This suggests that concurrent phosphorylation of FLNc at S2234 and S2237 prevails in vivo with pS2234 being the main site regulated by PI3K/Akt. In vitro kinase assays coupled to LC-MS (n=4) confirmed hFLNC-S2233 as prominent substrate site of Akt, while PKC alpha preferentially phosphorylateds S2236 in vitro. Accordingly, incubation with both kinases led to an increase of the doubly phosphorylated (pS2233 and pS2236) form. To validate these findings in myocytes, we performed an in cellulo kinase assays with pharmacologic interventions using Gö6976, PMA, IGF.1 and MK-2206, respectively, or a combination of the two inhibitors with PMA and IGF-1 followed by targeted MS analysis.
Experiment Description
Mouse C2 cells transiently expressing BirA* FLNc d18-21 were treated for 1 h with 10 µM MK-2206 (Selleck) or 10 µM Gö6976 (Merck) for 1 h or with 300 nM PMA (Sigma Aldrich) or IGF-1 (sigma Aldrich) for 15 min. In experiments using both, inhibitor and activator, cells were first treated with the respective inhibitor (MK-2206, Gö6976) for 1 h and PMA or IF-1 was added for the last 15 min of the treatment. Cells were lysed on ice with 500 µl modified RIPA buffer. Enrichment of the Myc-tagged FLNc fragment was performed with 10 µl Myc-Dynabeads (Invitrogen) according to the manufacturer’s protocol. On-bead tryptic digestion was performed in 200 µl ammonium bicarbonate solution (50 mM) for 3.5 h at 42°C and 1,400 rpm on a thermoshaker using sequencing grade trypsin,(Promega) in a 1:50 (w/w) ratio. Phosphopeptides were enriched as described above and mixed with 47.5-95 fmol phosphopeptides of a phosphopeptide standard comprising 181 phosphopeptides (Intavis). For targeted MS analysis on a QExactive Plus instrument, an inclusion list comprising 40 different precursor masses was generated with Skyline 2.6.0.6709. One scan cycle consisted of a full MS1 scan at a resolution of 70,000, an automatic gain control (AGC) target of 3e6 ions, a max. ion time of 20 ms and a scan range from m/z 400 to 1600, followed by 10 PRM scans. Each PRM scan targeted one precursor of the inclusion list at a resolving power of 17,500, an AGC target of 2e5, a max. ion time of 49 ms and an isolation window of 2 m/z. Raw files were analyzed with Skyline and intensities of hFLNc phosphopeptides were normalized to the summed intensities of eight phosphopeptides (SEGpSPVLPHEPAK, TGMGSGpSAGKEGGPFK, pSTVASMMHR, VIEDNEpYTAR, LIEDNEpYTAR, pSFNGSLKNVAVDELSR, pSGGQRHSPLSQR, AYpTHQVVTR) from the standard under control conditions.
Created on 3/4/20, 1:17 PM
Clustergrammer Heatmap
 
Download
histone_garcia_v0-9-2_greer_onlyhistlibrary_2021-01-11_15-29-49.sky.zip2021-02-17 19:58:15101362386,13112
180727_H460_cisplatin_analysis_2021-02-16_12-20-31.sky.zip2021-02-16 20:32:511,48717,12017,12085,5765
OLG_PSE_PRM_2021-02-07_13-57-40.sky.zip2021-02-07 20:43:065264022029
LINCS_GCP_Plate97_annotated_minimized_2021-02-02_14-10-30.sky.zip2021-02-02 11:18:18818116286694
LINCS_GCP_Plate96_annotated_minimized_2021-02-02_13-46-59.sky.zip2021-02-02 10:51:36818116285693
BSA_QC.sky.zip2021-01-29 10:48:30166625
P155_04_Panorama_2021-01-25_16-28-55.sky.zip2021-01-27 20:07:55214147521
LINCS_GCP_Plate67_annotated_minimized_2018-07-18_16-39-05.sky.zip2021-01-23 11:44:41818116291496
BSA-QC_68fmol_Nov2020_Impact-II_2021-01-21_13-58-46.sky.zip2021-01-21 13:59:10131402166
Pilot Kinetics Experiment CVN Mice 120k_Final_2021-01-06_15-35-00.sky.zip2021-01-06 12:35:161012188
Pilot Experiment APOE3 3 Mice (21 DBS_3Plasma_2Brain)_Final_2021-01-06_15-29-12.sky.zip2021-01-06 12:29:3410162226
E4HN 69 Wk F_M_120k_Final_2021-01-06_15-27-19.sky.zip2021-01-06 12:27:5910172384
Miller-QEHF-Liver_MouseQuant-10092019_2019-10-14_12-39-29.sky.zip2020-12-24 08:41:122,78415,73615,736112,55724
Miller-QEHF-lysosomesMouseQuant-2-07152019_2019-07-15_16-47-56.sky.zip2020-12-24 08:41:113,42618,79218,792130,95824
LINCS_P100_PRM_Plate32_annotated_minimized_2018-05-02_20-45-26.sky.zip2020-12-23 22:30:1090961921,14696
LINCS_P100_PRM_Plate31_annotated_minimized_2018-05-02_18-00-17.sky.zip2020-12-23 22:00:20909619299684
LINCS_P100_DIA_Plate65_annotated_minimized_2019-10-21_16-54-32.sky.zip2020-12-23 21:58:5590961921,58694
LINCS_P100_PRM_Plate29_03H_annotated_minimized_2018-05-02_21-16-28.sky.zip2020-12-23 21:34:3590961921,53696
LINCS_P100_PRM_Plate28_annotated_minimized_2018-05-02_18-51-02.sky.zip2020-12-23 21:10:3590961921,15896
LINCS_P100_PRM_Plate18_annotated_minimized_2020-01-08_17-11-19.sky.zip2020-12-23 20:45:4290961921,53896
LINCS_P100_DIA_Plate67_annotated_minimized_2018-08-02_13-56-24.sky.zip2020-12-23 20:22:5990961922,75496
LINCS_P100_PRM_Plate25_annotated_minimized_2018-05-02_18-24-10.sky.zip2020-12-23 19:57:1690961921,24296
LINCS_P100_DIA_Plate66_annotated_minimized_2018-08-31_10-36-13.sky.zip2020-12-23 19:28:3390961922,76496
LINCS_P100_DIA_Plate64_annotated_minimized_2018-05-02_20-34-19.sky.zip2020-12-23 18:45:44909619298295
LINCS_P100_DIA_Plate63a_annotated_minimized_2019-11-14_15-28-26.sky.zip2020-12-23 18:44:3190961922,76494
LINCS_P100_DIA_Plate62_annotated_minimized_2018-04-20_15-55-05.sky.zip2020-12-23 18:08:05909619298696
LINCS_P100_DIA_Plate61_annotated_minimized_2018-02-06_17-09-06.sky.zip2020-12-23 18:06:41909619299095
LINCS_P100_DIA_Plate60_annotated_minimized_2017-11-29_16-22-26.sky.zip2020-12-23 18:04:43909619297895
LINCS_P100_DIA_Plate59a_annotated_minimized_2018-11-30_14-13-58.sky.zip2020-12-23 18:02:4890961922,76494
LINCS_P100_DIA_Plate58_annotated_minimized_2017-11-28_11-50-08.sky.zip2020-12-23 17:37:47909619283495
LINCS_P100_DIA_Plate34_annotated_minimized_2019-08-30_17-25-21.sky.zip2020-12-23 17:36:23909619275296
LINCS_P100_DIA_Plate33_annotated_minimized_2018-05-02_17-47-07.sky.zip2020-12-23 17:35:27909619279696
LINCS_P100_DIA_Plate30_annotated_minimized_2018-05-02_18-33-32.sky.zip2020-12-23 17:34:11909619278596
LINCS_P100_DIA_Plate27_annotated_minimized_2018-05-02_19-16-47.sky.zip2020-12-23 17:32:2190961921,06496
LINCS_P100_DIA_Plate24_annotated_minimized_2018-05-02_19-07-44.sky.zip2020-12-23 16:42:31909619273296
LINCS_P100_DIA_Plate23_annotated_minimized_2018-05-02_18-13-55.sky.zip2020-12-23 16:41:36909619296096
LINCS_P100_DIA_Plate22_annotated_minimized_2018-05-02_22-33-32.sky.zip2020-12-23 16:40:3390961921,09695
LINCS_P100_DIA_Plate20_annotated_minimized_2018-05-02_21-04-33.sky.zip2020-12-23 16:02:0390961921,07496
LINCS_P100_DIA_Plate19_annotated_minimized_2018-05-02_17-18-22.sky.zip2020-12-23 15:42:0390961921,16096
LINCS_P100_DIA_Plate17_annotated_minimized_2018-05-02_17-35-29.sky.zip2020-12-23 15:22:0390961921,05495
LINCS_P100_DIA_Plate16_annotated_minimized_2018-05-02_19-43-10.sky.zip2020-12-23 15:01:3290961921,12295
LINCS_P100_DIA_Plate15_annotated_minimized_2018-05-02_19-32-22.sky.zip2020-12-23 13:42:2190961921,20296
LINCS_GCP_Plate66_annotated_minimized_2018-09-05_11-44-04.sky.zip2020-12-23 12:29:44818116284896
LINCS_GCP_Plate65_annotated_minimized_2019-10-17_15-57-42.sky.zip2020-12-23 12:28:15818116282496
LINCS_GCP_Plate64_annotated_minimized_2018-04-20_14-41-08.sky.zip2020-12-23 12:26:30818116283289
LINCS_GCP_Plate63_annotated_minimized_2019-09-12_11-57-23.sky.zip2020-12-23 12:24:58818116288296
LINCS_GCP_Plate62_annotated_minimized_2018-04-20_14-38-35.sky.zip2020-12-23 12:23:20818116286696
LINCS_GCP_Plate61_annotated_minimized_2018-01-10_11-34-56.sky.zip2020-12-23 12:21:57818116276996
LINCS_GCP_Plate60_annotated_minimized_2018-04-20_14-36-43.sky.zip2020-12-23 12:20:32818116287696
LINCS_GCP_Plate59_annotated_minimized_2019-09-26_16-33-28.sky.zip2020-12-23 12:19:10818116279095
LINCS_GCP_Plate58_annotated_minimized_2018-01-02_14-26-56.sky.zip2020-12-23 12:17:40818116286896
LINCS_GCP_Plate34_annotated_minimized_2019-10-17_13-06-51.sky.zip2020-12-23 12:16:10606012051896
LINCS_GCP_Plate33_annotated_minimized_2018-05-07_15-20-54.sky.zip2020-12-23 12:15:29606012050496
LINCS_GCP_Plate32_annotated_minimized_2018-05-07_15-51-20.sky.zip2020-12-23 12:14:32606012051696
LINCS_GCP_Plate31_annotated_minimized_2018-05-07_16-53-24.sky.zip2020-12-23 12:13:39606012051896
LINCS_GCP_Plate30_annotated_minimized_2018-05-07_16-32-39.sky.zip2020-12-23 12:12:51606012050696
LINCS_GCP_Plate29_annotated_minimized_2018-05-15_13-51-04.sky.zip2020-12-23 12:12:12606012051695
LINCS_GCP_Plate28_annotated_minimized_2018-05-07_15-02-14.sky.zip2020-12-23 12:11:32606012050696
LINCS_GCP_Plate27_annotated_minimized_2018-05-07_14-51-21.sky.zip2020-12-23 12:10:47606012049296
LINCS_GCP_Plate25_annotated_minimized_2018-05-07_16-09-52.sky.zip2020-12-23 12:09:55616112252896
LINCS_GCP_Plate24_annotated_minimized_2018-05-07_16-43-23.sky.zip2020-12-23 12:08:50595911848493
LINCS_GCP_Plate23_annotated_minimized_2018-05-07_14-31-53.sky.zip2020-12-23 12:07:52595911850296
LINCS_GCP_Plate22_annotated_minimized_2018-05-15_14-16-43.sky.zip2020-12-23 12:06:52606012050693
LINCS_GCP_Plate20_annotated_minimized_2018-05-07_15-41-44.sky.zip2020-12-23 12:05:51606012051496
LINCS_GCP_Plate19_annotated_minimized_2018-05-07_14-42-13.sky.zip2020-12-23 12:04:35606012052296
LINCS_GCP_Plate18_annotated_minimized_2018-05-07_14-22-16.sky.zip2020-12-23 12:03:50606012050696
LINCS_GCP_Plate17_annotated_minimized_2018-05-07_14-10-50.sky.zip2020-12-23 12:02:40606012051696
LINCS_GCP_Plate16_annotated_minimized_2018-05-09_11-16-44.sky.zip2020-12-23 12:01:46595911851696
LINCS_GCP_Plate15_annotated_minimized_2018-05-02_22-46-29.sky.zip2020-12-23 12:00:02606012053296
Proteins_PRM_Targeted_Treatment_Run_1_no_precursors_2020-09-25_09-21-58.sky.zip2020-12-18 08:02:333310310347437
Swab_host_PvsN_figure_2020-12-06_12-41-22.sky.zip2020-12-13 15:24:0010282816220
COVID_swab_viral_MRM_2020-12-11_23-25-32.sky.zip2020-12-13 15:24:005131312013
EGFR pathway peptide standards at different DDM concentrations Final_2020-11-28_19-41-16.sky.zip2020-11-30 19:49:41101010325
schilling_swath_silac-ecoli_6600_2020-10-23_12-53-04.sky.zip2020-11-22 02:16:567292,1523,03921,74141
20200828_QEHFX_lkp_pSILAC-DIA_btz_2020-10-29_10-27-57.sky.zip2020-11-22 02:16:564,08520,25840,417130,13220
20200828_QEHFX_lkp_pSILAC-DIA_curve_2020-11-04_16-10-32.sky.zip2020-11-22 02:16:566,32343,96187,681564,73484
20200828_QEHFX_lkp_pSILAC-DIA_curve_2020-10-13_09-33-04.sky.zip2020-11-22 02:16:566,32343,96187,681301,78784
20200421_ToxXevo_AZ_Delta_87.sky.zip2020-11-21 17:01:46111123489
Polyquant_Different_on_column_loading.sky.zip2020-11-21 17:01:40720376528
20200818_ToxXevo_eSwab_Comparison_Sample_Preparation.sky.zip2020-11-21 17:01:35111123327
TCA_Aceton_Digest_Time.sky.zip2020-11-21 17:01:32113143940
HCl_TCA.sky.zip2020-11-21 17:01:32113133712
MRM_XevoTQS_S63879_Patient_Samples.sky.zip2020-11-21 17:01:29110103030
MRM_XevoTQS_Dilution_series_Pure_eSwab_UTM.sky.zip2020-11-21 17:01:26110103050
Covid19_MRM_Template.sky.zip2020-11-21 17:01:23117228500
Skyline_75min_patientsamples_UZLeuven_Panorama.sky.zip2020-11-21 17:00:32112732883,37720
Leiden_eSwab_dilution.sky.zip2020-11-21 16:52:03719356210
Negative_patients.sky.zip2020-11-21 16:51:367203766105
Positive_Patients_below_Ct_30.sky.zip2020-11-21 16:51:3672037111100
200403_TTOF6600_SWATH_Dilution_20min_Panorama.sky.zip2020-11-21 16:49:38112732883,37727
200403_TTOF6600_SWATH_Dilution_75min_dilution_Panorama.sky.zip2020-11-21 16:49:38112732883,37727
Bioer_patient_dilution.sky.zip2020-11-21 16:36:23113132620
Virocult_patient_dilution.sky.zip2020-11-21 16:36:23113132621
UTM_patient_dilution.sky.zip2020-11-21 16:36:23113132621
eSwab_patient_dilution.sky.zip2020-11-21 16:36:23113132620
Lab_01.sky.zip2020-11-21 16:35:581661910
Lab_15.sky.zip2020-11-21 16:35:58616173810
Lab_14.sky.zip2020-11-21 16:35:58113142611
Lab_13.sky.zip2020-11-21 16:35:58113164911
Lab_12.sky.zip2020-11-21 16:35:58115163331

 

Fig4C.

Cell-based kinase assay. PKC activator PMA, PKCa inhibitor Gö6976 and Akt activator IGF-1 and inhibitor MK-2206 were used to activate or block signaling pathways in C2 cells. For targeted MS analysis, phosphopeptides were enriched by Myc-tag and TiO2-based enrichment.

Figure 4D.

Immunoblot analysis of PKCα and Akt activities in C2 cells following pharmacologic interventions as indicated in 4C. Pan- and phospho-specific antibodies were used to detect total protein amounts and phosphoisoforms. GAPDH was used as loading control.

Figure 4e.

Targeted MS data of hFLNc phosphopeptides comprising the phosphorylation sites pS2233, pS2233/pS2236 and pS2236. MS data were quantified using Skyline and normalized to an internal phosphopeptide standard and the mock-treated control (DMSO). Intensities of phosphopeptides distinctive for a specific phosphorylation site in hFLNc d18-21 WT were added up per experiment and represented as normalized mean log2 ratio (treatment/control) ± SEM (n=4; *, p ≤ 0.05; **, p ≤ 0.01)

 

This data is available under the CC BY 4.0 license.